Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

CYLD inhibits NFKB1. 3 / 3

| 3

➶

reach

"Loss of CYLD up-regulates NFKB signaling and enhance metastasis in breast cancer [37]."

31191821

➶

reach

"CYLD is downregulated in several cancers and inhibits the NFkB pathway [XREF_BIBR, XREF_BIBR]."

27923454

➶

reach

"Even though the extensively studied deubiquitinases CYLD and A20 are also known to negatively regulate NFkB activation, as does MCPIP, the target substrate and physiological functions of virtually all deubiquitinases remain obscure."

26387135

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...

Other Services

This Service

This Project

IndraLab

Statements

CYLD inhibits NFKB1. 3 / 3

Our Sources:

Databases

Reading